The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Open accessAbstract
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The authors flow-sorted the edited cells on the basis of the BCL11A-dependent switch to fetal haemoglobin, sequenced guides enriched in cells that had or hadn’t switched, and on the basis of those enrichments, successfully identified a primate-specific GATA1 motif critical for that enhancer’s function.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Cas9 introduces a targeted double-strand break, which is repaired by homology-directed repair using the donor templates, resulting in the incorporation of a single variant at the endogenous genomic locus (54, 55).”
From Massively parallel functional genomic assays in endocrinology: from promise to delivery (2026) · cites this paper as [54]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first such screen targeted gRNAs to effectively tile small indels across a known cluster of enhancers of BCL11A195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Canver et al 9 recently showed BCL11A enhancer disruption by CRISPR/Cas9 could induce fetal haemoglobin in both mice and primary human erythroblast cells.”
From What is CRISPR/Cas9? (2016) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The initial CRISPR screens of regulatory elements delivered an individual gRNA per cell195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
The cited source says what the claim attributes to it.
In the citing paper
“To date, all such screens use Cas9-induced perturbations, including active Cas9 for sequence disruption195, or nuclease dead-Cas9 (dCas9) tethered to an epigenetic repressor105 or activator domain92.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
In the citing paper
“In contrast, nine recently published CRISPR screens of noncoding sequences cumulatively studied regulatory effects on a total of 17 genes (Canver et al., 2015; Diao et al., 2016, 2017; Fulco et al., 2016; Gasperini et al., 2017; Klann et al., 2017; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
In the citing paper
“First, they focus on the regulation of a single gene per experiment, typically entailing the development of a gene-specific assay.”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Flagged first, then by citations
2 of the 65 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 883
Exploring noncoding variants in genetic diseases: from detection to functional insights
Wu, K., Bu, F., Wu, Y., Zhang, G., Wang, X., He, S., Liu, M., Chen, R., & Yuan, H. (2024) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2024.01.001 · Cited by 40
Single-cell CRISPR screening in drug resistance
Wang, W. Y., & Wang, X. (2017) · Cell Biology and Toxicology · doi:10.1007/s10565-017-9396-7 · Cited by 38
CRISPR/Cas9‐Mediated Genome Editing in Epstein‐Barr Virus‐Transformed Lymphoblastoid B‐Cell Lines
Jiang, S., Wang, L. W., Walsh, M. J., Trudeau, S. J., Gerdt, C., Zhao, B., & Gewurz, B. E. (2018) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.51 · Cited by 38
Wegner, M., Diehl, V., Bittl, V., de Bruyn, R., Wiechmann, S., Matthess, Y., Hebel, M., Hayes, M. G. B., Schaubeck, S., Benner, C. W., et al. (2019) · eLife · doi:10.7554/elife.42549 · Cited by 38
Hematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies
Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., Tisdale, J. F., & Uchida, N. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.001 · Cited by 39
Pharmacological and molecular approaches for the treatment of β‐hemoglobin disorders
Lohani, N., Bhargava, N., Munshi, A., & Ramalingam, S. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26292 · Cited by 38
The retroviral vector family: something for everyone
Elsner, C., & Bohne, J. (2017) · Virus Genes · doi:10.1007/s11262-017-1489-0 · Cited by 36
CRISPR/Cas9-based gene-editing technology for sickle cell disease
Ma, L., Yang, S., Peng, Q., Zhang, J., & Zhang, J. (2023) · Gene · doi:10.1016/j.gene.2023.147480 · Cited by 45
CRISPR-Cas Technology as a Revolutionary Genome Editing tool: Mechanisms and Biomedical Applications
Ebrahimi, S., Khosravi, M. A., Raz, A., Karimipoor, M., & Parvizi, P. (2023) · ̒Ulūm va funūn-i bastah/bandī · doi:10.61186/ibj.27.5.219 · Cited by 40
Sokhi, U. K., Liber, M. P., Frye, L., Park, S., Kang, K., Pannellini, T., Zhao, B., Norinsky, R., Ivashkiv, L. B., & Gong, S. (2018) · Nature Communications · doi:10.1038/s41467-018-03081-7 · Cited by 37
Genetic therapies for sickle cell disease
Esrick, E. B., & Bauer, D. E. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.04.014 · Cited by 39
Self-citationGudmundsdottir, B., Gudmundsson, K. O., Klarmann, K. D., Singh, S. K., Sun, L., Singh, S., Du, Y., Coppola, V., Stockwin, L. H., Nguyen, N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.043 · Cited by 37
Mettananda, S., Yasara, N., Fisher, C. A., Taylor, S., Gibbons, R. J., & Higgs, D. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-48204-2 · Cited by 37
Gene Therapy of the Hemoglobinopathies
Kunz, J. B., & Kulozik, A. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000479 · Cited by 40
Lopes, R., Sprouffske, K., Sheng, C., Uijttewaal, E., Wesdorp, A. E., Dahinden, J., Wengert, S., Díaz-Miyar, J., Yildiz, U., Bleu, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf5733 · Cited by 31
Non-Transfusion-Dependent Thalassemia: A Panoramic Review
Shash, H. A. (2022) · Medicina · doi:10.3390/medicina58101496 · Cited by 37
CRISPR ‐Cas9 technology and its application in haematological disorders
Zhang, H., & McCarty, N. (2016) · British Journal of Haematology · doi:10.1111/bjh.14297 · Cited by 37
Regulatory elements in molecular networks
Doane, A. S., & Elemento, O. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1374 · Cited by 40
Impact of Genetic Variation on CRISPR-Cas Targeting
Canver, M. C., Joung, J. K., & Pinello, L. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0016 · Cited by 36
Self-citationApplication of CRISPR/Cas to Understand Cis- and Trans-Regulatory Elements in Plants
Wolter, F., & Puchta, H. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8657-6_2 · Cited by 35
Daniel-Moreno, A., Lamsfus‐Calle, A., Raju, J., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0510-8 · Cited by 40
GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia
Belver, L., Yang, A. Y., Alberó, R., Herranz, D., Brundu, F. G., Quinn, S. A., Pérez‐Durán, P., Álvarez, S., Gianni, F., Rashkovan, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0471 · Cited by 38
Human TYRP1: Two functions for a single gene?
Gautron, A., Migault, M., Bachelot, L., Corre, S., Galibert, M., & Gilot, D. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12951 · Cited by 34
Gene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 38
Functional interrogation of non-coding DNA through CRISPR genome editing
Canver, M. C., Bauer, D. E., & Orkin, S. H. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.008 · Cited by 36
Self-citationCRISPR Genome Engineering for Human Pluripotent Stem Cell Research
Chaterji, S., Ahn, E. H., & Kim, D. (2017) · Theranostics · doi:10.7150/thno.18456 · Cited by 35
MAUDE: inferring expression changes in sorting-based CRISPR screens
de Boer, C. G., Ray, J. P., Hacohen, N., & Regev, A. (2020) · Genome biology · doi:10.1186/s13059-020-02046-8 · Cited by 39
Snetkova, V., & Skok, J. A. (2018) · Epigenomics · doi:10.2217/epi-2017-0157 · Cited by 34
Exosomes for CRISPR-Cas9 Delivery: The Cutting Edge in Genome Editing
Aslan, C., Zolbanin, N. M., Faraji, F., & Jafari, R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00932-7 · Cited by 35
Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells
Zeng, J., Nguyen, M. A., Liu, P., da Silva, L. F., Levesque, S., Lin, L. Y., Justus, D. G., Petri, K., Clement, K., Porter, S. N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.001 · Cited by 36
Self-citationUse of genome-editing tools to treat sickle cell disease
Tasan, I., Jain, S., & Zhao, H. (2016) · Human Genetics · doi:10.1007/s00439-016-1688-0 · Cited by 36
Gene therapy and gene editing strategies for hemoglobinopathies
Lidonnici, M. R., & Ferrari, G. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.12.001 · Cited by 34
Technical considerations for the use of CRISPR/Cas9 in hematology research
Gundry, M. C., Dever, D. P., Yudovich, D., Bauer, D. E., Haas, S., Wilkinson, A. C., & Singbrant, S. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.07.006 · Cited by 26
Self-citationElevating fetal hemoglobin: recently discovered regulators and mechanisms
Khandros, E., & Blobel, G. A. (2024) · Blood · doi:10.1182/blood.2023022190 · Cited by 32
A genome editing primer for the hematologist
Hoban, M. D., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2016-01-678151 · Cited by 32
Self-citationThe E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells
Lan, X., Khandros, E., Huang, P., Peslak, S. A., Bhardwaj, S. K., Grevet, J. D., Abdulmalik, O. Y., Wang, H., Keller, C. A., Giardine, B. M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019032318 · Cited by 33
King, A. J., & Higgs, D. R. (2018) · Hematology · doi:10.1182/asheducation-2018.1.353 · Cited by 35
PsychENCODE and beyond: transcriptomics and epigenomics of brain development and organoids
Jourdon, A., Scuderi, S., Capauto, D., Abyzov, A. S., & Vaccarino, F. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0763-3 · Cited by 29
Molecular Medicine: Found in Translation
Orkin, S. H. (2021) · Med · doi:10.1016/j.medj.2020.12.011 · Cited by 36
Self-citationAltrock, P. M., Brendel, C., Renella, R., Orkin, S. H., Williams, D. A., & Franziska Michor, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24449 · Cited by 31
Self-citationThe Functionality and Evolution of Eukaryotic Transcriptional Enhancers
Buffry, A. D., Mendes, C. C., & McGregor, A. P. (2016) · Advances in genetics · doi:10.1016/bs.adgen.2016.08.004 · Cited by 34
Orthogonal Cas9–Cas9 chimeras provide a versatile platform for genome editing
Bolukbasi, M. F., Liu, P., Luk, K., Kwok, S. F., Gupta, A., Amrani, N., Sontheimer, E. J., Zhu, L. J., & Wolfe, S. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07310-x · Cited by 30
Illuminating the genome-wide activity of genome editors for safe and effective therapeutics
Cheng, Y., & Tsai, S. Q. (2018) · Genome biology · doi:10.1186/s13059-018-1610-2 · Cited by 32
Huo, H., & Hu, G. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0246-5 · Cited by 30
Genome Editing for β-Hemoglobinopathies: Advances and Challenges
Frati, G., & Miccio, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030482 · Cited by 31
In vivo CRISPR screening for phenotypic targets of the mir-35-42 family in C. elegansPreprint
Yang, B., Schwartz, M. L., & McJunkin, K. (2020) · Genes & Development · doi:10.1101/gad.339333.120 · Cited by 31
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia
Zeng, S., Lei, S.-Y., Qu, C., Wang, Y., Teng, S., & Huang, P. C. (2023) · Human Genetics · doi:10.1007/s00439-023-02610-9 · Cited by 31
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 32
Gene editing and its application for hematological diseases
Osborn, M. J., Belanto, J. J., Tolar, J., & Voytas, D. F. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2017-z · Cited by 32
Sieber, K. B., Batorsky, A., Siebenthall, K. T., Hudkins, K. L., Vierstra, J. D., Sullivan, S. T., Sur, A., McNulty, M. T., Sandstrom, R. S., Reynolds, A. P., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018030309 · Cited by 30
Using CRISPR to understand and manipulate gene regulation
Akıncı, E., Hamilton, M. C., Khowpinitchai, B., & Sherwood, R. I. (2021) · Development · doi:10.1242/dev.182667 · Cited by 36
Fu, J., Zhang, Y., Guang, C., Meng, G., & Shi, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254815 · Cited by 30
Liu, Q., Chan, A., Chang, W.-H., Yang, L., Pokharel, S. P., Miyashita, K., Mattson, N., Xu, X., Li, M., Lu, W., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01378-z · Cited by 30
Yasara, N., Wickramarathne, N., Mettananda, C. D., Silva, I., Hameed, N., Attanayaka, K., Rodrigo, R., Wickramasinghe, N., Perera, L., Manamperi, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06774-8 · Cited by 35
Frati, G., Brusson, M., Sartre, G., Mlayah, B., Félix, T., Chalumeau, A., Antoniou, P., Hardouin, G., Concordet, J., Romano, O., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.015 · Cited by 32
Tang, S., Chen, X., Tong, X., & Zhu, L. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.112724 · Cited by 31
The Endoplasmic Reticulum Cargo Receptor SURF4 Facilitates Efficient Erythropoietin Secretion
Lin, Z., King, R., Tang, V. T., Myers, G., Balbin-Cuesta, G., Friedman, A. D., McGee, B. M., Desch, K. C., Ozel, A. B., Siemieniak, D. R., et al. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00180-20 · Cited by 30
Genetic therapies for the first molecular disease
Doerfler, P. A., Sharma, A., Porter, J. S., Zheng, Y., Tisdale, J. F., & Weiss, M. J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146394 · Cited by 30
Parallel characterization of cis-regulatory elements for multiple genes using CRISPRpath
Ren, X., Wang, M., Li, B., Jamieson, K., Zheng, L., Jones, I. R., Li, B., Takagi, M. A., Lee, J., Maliskova, L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi4360 · Cited by 28
CRISPR-FOCUS: A web server for designing focused CRISPR screening experiments
Cao, Q., Ma, J., Chen, C.-H., Xu, H., Chen, Z., Li, W., & Liu, X. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184281 · Cited by 29
Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies
Demirci, S., Leonard, A. K., & Tisdale, J. F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa088 · Cited by 32
Identifying Novel Enhancer Elements with CRISPR-Based Screens
Klein, J. C., Chen, W., Gasperini, M. J., & Shendure, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00778 · Cited by 33
CRISPR Tools for Systematic Studies of RNA RegulationPreprint
Engreitz, J., Abudayyeh, O. O., Gootenberg, J. S., & Zhang, F. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035386 · Cited by 31
Self-citationHunchback is counter-repressed to regulate even-skipped stripe 2 expression in Drosophila embryos
Vincent, B. J., Staller, M. V., López-Rivera, F., Bragdon, M. D. J., Pym, E. C. G., Biette, K. M., Wunderlich, Z., Harden, T. T., Estrada, J., & DePace, A. H. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007644 · Cited by 29
Hojo, M. A., Masuda, K., Hojo, H., Nagahata, Y., Yasuda, K., Ohara, D., Takeuchi, Y., Hirota, K., Suzuki, Y., Kawamoto, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10525-1 · Cited by 26
Activation of the imprinted Prader-Willi syndrome locus by CRISPR-based epigenome editing
Rohm, D., Black, J. B., McCutcheon, S. R., Barrera, A., Berry, S. S., Morone, D. J., Nuttle, X., de Esch, C. E., Tai, D. J. C., Talkowski, M. E., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100770 · Cited by 28
CRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 31
Self-citationHistorical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy
Kohn, D. B. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.006 · Cited by 28
Advances in the gene therapy of monogenic blood cell diseases
Bueren, J. A., Bustamante, O. Q., Almarza, E., Navarro, S., Rı́o, P., Segovia, J. C., & Güenechea, G. (2019) · Clinical Genetics · doi:10.1111/cge.13593 · Cited by 28
Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges
Pei, W., Zhang, Y., Yin, T., & Yu, Y. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz035 · Cited by 28
Demirci, S., Gudmundsdottir, B., Li, Q., Haro‐Mora, J. J., Nassehi, T., Drysdale, C. M., Yapundich, M., Gamer, J., Seifuddin, F., Tisdale, J. F., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.013 · Cited by 29
Genome editing approaches to β-hemoglobinopathies
Brusson, M., & Miccio, A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.025 · Cited by 29
Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy
Rosanwo, T. O., & Bauer, D. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.002 · Cited by 30
Self-citationEvolution of nanobodies specific for BCL11A
Yin, M., Izadi, M., Tenglin, K., Viennet, T., Zhai, L., Zheng, G., Arthanari, H., Dassama, L. M. K., & Orkin, S. H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218959120 · Cited by 28
Self-citationEpigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis
Li, M., Yang, L., Chan, A., Pokharel, S. P., Liu, Q., Mattson, N., Xu, X., Chang, W., Miyashita, K., Singh, P. A., et al. (2023) · Advanced Science · doi:10.1002/advs.202206584 · Cited by 26
Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies
Paschoudi, K., Yannaki, E., & Psatha, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119527 · Cited by 30
High-throughput genetic screens using CRISPR–Cas9 system
Kweon, J., & Kim, Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1029-z · Cited by 27
Decoding the noncoding genome via large-scale CRISPR screens
Shukla, A., & Huangfu, D. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.001 · Cited by 27
Wang, H., Liu, Z., Li, C., Gil, S., Papayannopoulou, T., Doering, C. B., & Lieber, A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000706 · Cited by 27
High-resolution interrogation of functional elements in the noncoding genomePreprint
Sanjana, N. E., Wright, J. B., Zheng, K., Shalem, O., Fontanillas, P., Joung, J., Cheng, C. S., Regev, A., & Zhang, F. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/049130 · Cited by 27
Self-citationLin, L., Petersen, T. S., Jensen, K. T., Bolund, L., Kühn, R., & Luo, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.02.024 · Cited by 25
Promise of gene therapy to treat sickle cell disease
Romero, Z. G., DeWitt, M. A., & Walters, M. C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1536119 · Cited by 27
Farzanehpour, M., Miri, A., Alvanegh, A. G., & Gouvarchinghaleh, H. E. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115555 · Cited by 27
Immunoresponse to Gene-Modified Hematopoietic Stem Cells
Drysdale, C. M., Tisdale, J. F., & Uchida, N. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.010 · Cited by 28
Godbole, N., Quinn, A., Carrión, F., Pelosi, E., & Salomón, C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.10.002 · Cited by 25
CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells
Chung, J. E., Magis, W., Vu, J. T., Heo, S., Wartiovaara, K., Walters, M. C., Kurita, R., Nakamura, Y., Boffelli, D., Martin, D. I. K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208237 · Cited by 25
Self-citationBeta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation
Chauhan, W., Shoaib, S., Fatma, R., Zaka‐ur‐Rab, Z., & Afzal, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15343 · Cited by 27
Lin, J. J., & Musunuru, K. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.001946 · Cited by 27
Mettananda, S., Pathiraja, H., Peiris, R., Wickramarathne, N., Bandara, D. C., de Silva, U., Mettananda, C. D., & Premawardhena, A. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27643 · Cited by 25
Advances in therapeutic application of CRISPR-Cas9
Sun, J., Wang, J., Zheng, D., & Hu, X. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz031 · Cited by 25
Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing
Zhang, H., Sun, R., Fei, J., Chen, H., & Lu, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115948 · Cited by 27
CRISP-view: a database of functional genetic screens spanning multiple phenotypes
Cui, Y., Cheng, X., Chen, Q., Song, B., Chiu, A., Gao, Y., Dawson, T., Chao, L., Zhang, W., Li, D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa809 · Cited by 24
BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice
Jang, Y., Feng, R., Palmer, L. E., Mayuranathan, T., Yao, Y., Mayberry, K. D., Zhou, S., Xu, J., Gossett, J. M., Kang, G., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015574 · Cited by 24
The use of CRISPR/Cas associated technologies for cell transplant applications
Cowan, P. J. (2016) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000347 · Cited by 24
Investigational drugs in phase I and phase II clinical trials for thalassemia
Motta, I., Scaramellini, N., & Cappellini, M. D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1335709 · Cited by 26
Moir-Meyer, G., Cheong, P. L., Olijnik, A.-A., Brown, J. M., Knight, S. J. L., King, A. J., Kurita, R., Nakamura, Y., Gibbons, R. J., Higgs, D. R., et al. (2018) · Methods and Protocols · doi:10.3390/mps1030028 · Cited by 24
Self-citationKyrochristos, I. D., Ziogas, D. E., & Roukos, D. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21549 · Cited by 25
Pathogenic BCL11A variants provide insights into the mechanisms of human fetal hemoglobin silencing
Shen, Y., Li, R., Teichert, K., Montbleau, K. E., Verboon, J. M., Voit, R. A., & Sankaran, V. G. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009835 · Cited by 23
Lim, C. K. W., McCallister, T. X., Saporito-Magriñá, C., McPheron, G. D., Krishnan, R., C., M. A. Z., Powell, J. E., Clark, L. V., Pérez‐Piñera, P., & Gaj, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.008 · Cited by 25
Gene Editing: Powerful New Tools for Nephrology Research and Therapy
Miyagi, A., Lu, A., & Humphreys, B. D. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016020146 · Cited by 25
Metadata
- Authors
- Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Broad Institute (US)
- RIKEN BioResource Research Center (JP)
- University of Tsukuba (JP)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Feng
- Orkin, Stuart H.
- Bauer, Daniel E.
- ORCID
- Venue
- Nature
- Published
- 2015-09-16
- Volume
- 527
- Issue
- 7577
- Pages
- 192-197
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4644101
- OpenAlex
- W1855348513
- Cited by
- 886
- References
- 65
- Citations by year
- 2026: 43 · 2025: 72 · 2024: 76 · 2023: 79 · 2022: 68 · 2021: 91 · 2020: 85 · 2019: 92 · 2018: 87 · 2017: 94 · 2016: 89 · 2015: 8
- FWCI
- 51.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- Howard Hughes Medical Institute
- U.S. Public Health Service (R01 A1084905)
- National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, R01HL119099)
- National Institute of Mental Health (DP1MH100706, R01MH110049)
- National Human Genome Research Institute (K99HG008171, R01HG005085, K99HG008399)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, 5R01-DK097768, R01DK097768, F30DK103359, K08DK093705)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- BCL11A, enhancers, CRISPR/Cas9, fetal hemoglobin, sickle cell disease, beta-thalassemia, enhancer architecture, erythroblasts
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Carrier Proteins, Cells, Cultured, DNA-Binding Proteins, Enhancer Elements, Genetic, Erythroblasts, Fetal Hemoglobin, Genetic Engineering, Humans, Molecular Sequence Data, Nuclear Proteins, Organ Specificity, Repressor Proteins, Species Specificity, Reproducibility of Results, Mutagenesis, Genome, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
